As a tumor suppressor, ECRG4 is downregulated in cancers due to promoter methylation [71, 72], and its immune activation and tumor inhibition functions may be attributed to its TLR4-targeted internalization domain [73]. This evidence concerns the gene TLR4 and cancer.